Source:

Press Release

May 01, 2021
1 min read
Save

First patient dosed in a phase 2 combined therapy trial for chronic HBV

Source:

Press Release

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Brii Biosciences, Vir Biotechnology and VBI Vaccines announced the first patient dosed in a phase 2 trial evaluating combination therapy for the treatment of patients with chronic hepatitis B infection, according to a press release.

This multi-center, randomized, open-label study will evaluate the safety and efficacy of BRII-835 (VIR-2218), an investigational small interfering RNA targeting HBV, combined with BRII-179 (VBI-2601), an investigational HBV immunotherapeutic, compared with BRII-835 alone. A prior study revealed both agents demonstrated proof of mechanism in HBV patients.

“We believe that a functional cure for HBV is possible and will require restoration of HBV-specific immunologic control in addition to viral suppression mechanisms. Data from our previous study suggest BRII-179 (VBI-2601) was able to restimulate both antibody and T-cell responses specific to HBV,” Francisco Diaz-Mitoma, MD, PHD, chief medical officer of VBI Vaccines, said in the release. “This combination study represents the first combination of a therapeutic HBV vaccine to restore HBV-immunity with antivirals designed to reduce the levels of HBV surface antigens.”